Long-term retention of cardiac resynchronization therapy

被引:93
作者
Knight, BP
Desai, A
Coman, J
Faddis, M
Yong, P
机构
[1] Univ Chicago, Dept Internal Med, Div Cardiol, Chicago, IL 60637 USA
[2] Univ Oklahoma, Dept Internal Med, Div Cardiol, Tulsa, OK 74136 USA
[3] Washington Univ, Div Cardiol, Dept Internal Med, St Louis, MO 63110 USA
[4] Guidant Corp, Dept Internal Med, Div Cardiol, St Paul, MN USA
关键词
D O I
10.1016/j.jacc.2004.03.054
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
OBJECTIVES The purpose of this study was to determine the frequency and causes of intermittent and permanent loss of cardiac resynchronization therapy (CRT) in patients who have undergone the successful implantation of a transvenous defibrillator that delivers CRT (CRT-D). BACKGROUND The causes of loss of CRT have not been described. METHODS The records of 512 patients who underwent an attempt at implantation of a transvenous CRT-D device as part of the VENTAK CHF/CONTAK CD Biventricular Pacing study were analyzed. RESULTS Device implantation was successful in 443 of 512 (87%) of patients. Among these 443 patients, CRT was interrupted in 161 (36%) patients during a mean follow-up of 2.5 +/- 1.1 years. Reasons included the development of an atrial tachyarrhythmia (18%), loss of left ventricular capture (10%), diaphragmatic stimulation (2%), loss of right ventricular capture (2%), infection (1%), intentional discontinuation of CRT (1%), loss of right atrial sensing (1%), and ventricular oversensing (0.2%). Most patients under-went an intervention that permitted the reinstitution of CRT, such that only 20 of the 443 patients (5%) experienced the permanent loss of CRT. Using an intention-to-treat analysis, the long-term retention of CRT was 83% during the course of 2.5 years. CONCLUSIONS Cardiac resynchronization therapy is interrupted in more than one-third of patients after the successful implantation of a CRT-D device. However, CRT can be reinstituted in most patients and has a high long-term retention rate. Because patients with slower heart rates were more likely to develop atrial tachyarrhythmias, a dual-chamber rate-modulated pacing mode (DDDR) may reduce interruptions of CRT. (C) 2004 by the American College of Cardiology Foundation.
引用
收藏
页码:72 / 77
页数:6
相关论文
共 15 条
  • [1] Cardiac resynchronization in chronic heart failure
    Abraham, WT
    Fisher, WG
    Smith, AL
    Delurgio, DB
    Leon, AR
    Loh, E
    Kocovic, DZ
    Packer, M
    Clavell, AL
    Hayes, DL
    Ellestad, M
    Messenger, J
    Trupp, RJ
    Underwood, J
    Pickering, F
    Truex, C
    McAtee, P
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2002, 346 (24) : 1845 - 1853
  • [2] Update of clinical trials from the American College of Cardiology 2003. EPHESUS, SPORTIF-III, ASCOT, COMPANION, UK-PACE and T-wave alternans
    Cleland, JGF
    Coletta, AP
    Nikitin, N
    Louis, A
    Clark, A
    [J]. EUROPEAN JOURNAL OF HEART FAILURE, 2003, 5 (03) : 391 - 398
  • [3] Atrial fibrillation is associated with an increased risk for mortality and heart failure progression in patients with asymptomatic and symptomatic left ventricular systolic dysfunction: A retrospective analysis of the SOLVD trials
    Dries, DL
    Exner, DV
    Gersh, BJ
    Domanski, MJ
    Waclawiw, MA
    Stevenson, LW
    [J]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 1998, 32 (03) : 695 - 703
  • [4] Cardiac resynchronization therapy for the treatment of heart failure in patients with intraventricular conduction delay and malignant ventricular tachyarrhythmias
    Higgins, SL
    Hummel, JD
    Niazi, IK
    Giudici, MC
    Worley, SJ
    Saxon, LA
    Boehmer, JP
    Higginbotham, MB
    De Marco, T
    Foster, E
    Yong, PG
    [J]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2003, 42 (08) : 1454 - 1459
  • [5] Long-term benefits of biventricular pacing in congestive heart failure: Results from the MUltisite STimulation in cardiomyopathy (MUSTIC) study
    Linde, C
    Leclercq, C
    Rex, S
    Garrigue, S
    Lavergne, T
    Cazeau, S
    McKenna, W
    Fitzgerald, M
    Deharo, JC
    Alonso, C
    Walker, S
    Braunschweig, F
    Bailleul, C
    Daubert, JC
    [J]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2002, 40 (01) : 111 - 118
  • [6] Toleration of high doses of angiotensin-converting enzyme inhibitors in patients with chronic heart failure - Results from the ATLAS trial
    Massie, BM
    Armstrong, PW
    Cleland, JGF
    Horowitz, JD
    Packer, M
    Poole-Wilson, PA
    Ryden, L
    [J]. ARCHIVES OF INTERNAL MEDICINE, 2001, 161 (02) : 165 - 171
  • [7] The effect of carvedilol on morbidity and mortality in patients with chronic heart failure
    Packer, M
    Bristow, MR
    Cohn, JN
    Colucci, WS
    Fowler, MB
    Gilbert, EM
    Shusterman, NH
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1996, 334 (21) : 1349 - 1355
  • [8] Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial - the Losartan Heart Failure Survival Study ELITE II
    Pitt, B
    Poole-Wilson, PA
    Segal, R
    Martinez, FA
    Dickstein, K
    Camm, AJ
    Konstam, MA
    Riegger, G
    Klinger, GH
    Neaton, J
    Sharma, D
    Thiyagarajan, B
    [J]. LANCET, 2000, 355 (9215) : 1582 - 1587
  • [9] The effect of spironolactone on morbidity and mortality in patients with severe heart failure
    Pitt, B
    Zannad, F
    Remme, WJ
    Cody, R
    Castaigne, A
    Perez, A
    Palensky, J
    Wittes, J
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1999, 341 (10) : 709 - 717
  • [10] Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol, European Trial (COMET): randomised controlled trial
    Poole-Wilson, PA
    Swedberg, K
    Cleland, JGF
    Di Lenarda, A
    Hanrath, P
    Komajda, M
    Lubsen, J
    Lutiger, E
    Metra, M
    Remme, WJ
    Torp-Pedersen, C
    Scherhag, A
    Skene, A
    [J]. LANCET, 2003, 362 (9377) : 7 - 13